New cancer drug MT-4561 enters first human tests
NCT ID NCT06943521
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human study, so the drug's effects and risks are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital
RECRUITINGChuo-Ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGCity, Japan
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Southern California
RECRUITINGLos Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT-4561 (given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early first-in-human trial with only 27 participants. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.